MiSight | 1-Day Contacts
The MiSight® 1 day contact lens stands out as the sole contact lens with FDA approval for addressing the gradual advancement of myopia (commonly known as nearsightedness) in children. This intervention aimed at slowing myopia progression in children holds the potential to decrease their susceptibility to serious eye conditions like macular degeneration, retinal detachment, and glaucoma in their later years. Additionally, effective control of high prescriptions enhances the likelihood of the child being eligible for future refractive surgeries, such as Lasik, when they reach adulthood.
Know the Facts
1. The First and Only
MiSight® 1 day takes the lead as the initial and sole soft contact lens with FDA approval designed to decelerate the progression of myopia in children aged 8-12 upon commencing treatment.
2. Backed by Clinical Evidence and Safety Assurance:
Over a span of 3 years, myopia progression witnessed an average reduction of 59%, eye lengthening decreased by an average of 52%, and 41% of eyes exhibited no progression. Extending this evaluation to a 6-year timeframe revealed that children using MiSight 1 day experienced an average progression of less than 1.00D.
A striking 90% of parents, whose children utilized MiSight® 1 day contact lenses, affirmed that their children expressed contentment with wearing these lenses.
4. Designed for Children:
Following a three-year period of using MiSight® 1 day contact lenses, a notable 90% of children continued to strongly prefer them over their conventional glasses.
FDA Approved MiSight® Clinical Trial
Clinically Validated through a Seven-Year Extensive Study. The MiSight® 1 day lens has undergone rigorous clinical examination, as evidenced by a comprehensive seven-year study, showcasing its effectiveness in impeding the progression of myopia when initially prescribed for children aged 8-12. Throughout a three-year duration, MiSight® demonstrated a remarkable 59% reduction in myopia progression when compared to a single vision 1 day lens. Moreover, it efficiently curtailed axial elongation by an average of 52%. Positioned as a pivotal component, MiSight® stands as the cornerstone in a holistic approach to managing myopia.